Indefinite Delivery Contract 75F40125D00022
- Not listed
- The key products and services being delivered under this Indefinite Delivery Contract (IDC) awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) are proteomics analysis services on human plasma and serum samples. The prime contractor, Somalogic Operating Co., Inc. (doing business as CM Life Sciences II Inc.), is a commercial-stage proteomics company that provides its proprietary SomaScan platform to measure thousands of proteins in small biospecimens....
- The Department of Health and Human Services Food and Drug Administration (FDA) awarded a single-award Indefinite Delivery Contract (IDC) to AB Sciex LLC, a division of Danaher Corporation, for a 5-year maintenance and service contract for liquid chromatography-tandem mass spectrometers (LC-MS/MS). The contract has a ceiling value of $2,503,000 and a period of performance through April 23, 2029. Under this IDC, the FDA awarded a $225,566.45 Firm Fixed Price Delivery Order to AB Sciex LLC for an...
- The U.S. Food and Drug Administration (FDA) has awarded a $1 million single-award Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Pacific Biosciences of California, Inc. to provide sequencing reagents, kits, and consumables to support the agency's genomic research and regulatory review activities. Under this contract, the FDA has issued multiple delivery orders for the purchase of Pacific Biosciences' proprietary single molecule, real-time (SMRT) sequencing consumables, including...
- This is a single-award Indefinite Delivery Contract (IDC) awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Metabolon, Inc., a small disadvantaged business. The contract has a ceiling value of $296,000.00 and a period of performance through August 1, 2030. The purpose of this IDC is to provide the FDA with indefinite delivery/indefinite quantity (IDIQ) services for metabolomic analysis of biological samples. Metabolon, as the prime contractor, will utilize its...
- The Department of Health and Human Services Food and Drug Administration awarded a blanket purchase agreement to AB Sciex LLC, a division of Danaher Corporation, to procure ultra-sensitive liquid chromatography-triple quadrupole mass spectrometry systems with ion-trap capabilities. Under multiple call contracts against this agreement totaling over $12M, AB Sciex will provide 29 mass spectrometry systems and 11 nitrogen generators to support FDA's regulatory science and public health protection...
- The U.S. Food and Drug Administration (FDA), a civilian federal agency, awarded a single-award Indefinite Delivery Contract (IDC) to Qiagen, LLC, a subsidiary of the multinational biotechnology company Qiagen N.V. The $1,250,000 IDC is for the procurement of laboratory services and Qiagen's molecular biology and sequencing library reagents. Under this IDC, the FDA has issued several firm fixed-price delivery orders for Qiagen to provide a variety of molecular biology reagents, extraction and...
- The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery, indefinite quantity contract to Koniag Management Solutions LLC with a potential value of $25,000,000. Task orders issued against the contract procure scientific support services including research, laboratory analysis, and subject matter expertise to support the FDA's regulatory, compliance and public health programs. Task orders awarded to Koniag Management Solutions LLC and described in...
- The Department of Health and Human Services Food and Drug Administration awarded an Indefinite Delivery Contract with a potential value of $25 million to Midnight Sun Technologies LLC. The contract is a single award, 8(a) sole source set aside for scientific support services to be performed across multiple locations including Silver Spring, MD, Vienna, VA, and Calverton, MD. The contract aims to procure subject matter expertise through various labor categories such as Scientist III, Researcher...
- The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery contract to Molecular Epidemiology Inc. to provide microbiological analysis and whole genome sequencing services. The single award IDV has a potential value of $10 million and a period of performance through May 2027. Five firm fixed price task orders have been issued against the contract to date for specific services. These include analysis of Cyclospora cayetanensis oocysts, shrimp...
- The Department of Health and Human Services Food and Drug Administration (FDA) awarded an Indefinite Delivery Contract (IDC) to Biomerieux Inc., a global leader in in vitro diagnostics, with a ceiling value of $2,000,000. The contract provides the FDA with access to Biomerieux's specialized diagnostic platforms, reagents, and test kits to support the agency's medical device testing, pathogen detection, and clinical laboratory operations. Through a series of firm-fixed-price delivery orders...
- 75F40125D00022Indefinite Delivery Contract
- 1Federal Contract Awards
The Food and Drug Administration awarded a 5-year Indefinite Delivery/Indefinite Quantity contract to Somalogic Operating Co., Inc. (doing business as CM Life Sciences II Inc.) on September 19, 2025, with a ceiling value of $2,002,500 and ultimate completion date of September 28, 2030. This single-award contract, which does not utilize set-aside provisions, procures proteomic services for analysis of clinical samples to support the FDA's regulatory science programs. Somalogic, headquartered in Boulder, Colorado, will provide advanced protein measurement and biomarker discovery services utilizing its proprietary SomaScan platform, an aptamer-based assay technology capable of simultaneously measuring up to 11,000 proteins in plasma, serum, and other biological specimens. The company's specialized expertise in high-throughput proteomics analysis with demonstrated sensitivity and reproducibility makes it a critical technology partner for federal research and regulatory evaluation initiatives. Under this Indefinite Delivery/Indefinite Quantity contract, the FDA has already issued a delivery order dated September 23, 2025, valued at $269,750 on a firm fixed price basis for genomic services, with completion scheduled for September 28, 2026. The place of performance for this initial task order is Silver Spring, Maryland. Somalogic's contract performance supports the FDA's evaluation of the safety and efficacy of medical products through advanced proteomic analysis, leveraging the company's established track record of providing protein biomarker discovery and diagnostic services across multiple research domains including neurodegenerative diseases, cardiovascular health, cancer research, infectious diseases, and immunology. This contract structure allows the FDA to issue additional delivery orders against the established ceiling value throughout the five-year period as regulatory science needs arise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Other Administrative Action | $0 | 9/19/25 |
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
Delivery Order 75F40125D00022-75F40125F19001 | Somalogic Operating Co., Inc. | $269.8k | 9/23/25 | 9/28/26 | 9/23/25 |